Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea Holdings Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by August 1, 2025 [3][5]. Group 1: Allegations Against Fortrea - The complaint alleges that Fortrea and its executives made false and misleading statements regarding revenue expectations from Pre-Spin Projects and overstated cost savings from exiting Transitional Service Agreements (TSAs) [5]. - It is claimed that Fortrea's previously announced EBITDA targets for 2025 were inflated, leading to an overstatement of the company's business model viability and financial prospects [5]. - The company's public statements were deemed materially false and misleading at all relevant times [5]. Group 2: Stock Performance and Analyst Downgrades - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the business model and a stock price drop of $2.73 per share (12.29%) to close at $19.48 [6]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, resulting in a stock price decline of $1.90 per share (8.06%) to close at $21.67 [7]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, leading to a significant stock price drop of $3.47 per share (25.05%) to close at $10.38 [8]. Group 3: Legal Proceedings and Investor Actions - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1][3]. - The court-appointed lead plaintiff will be the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Fortrea's conduct [10].

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=152588&from=3 CLASS PERIOD: Ju ...

Core Viewpoint - Fortrea has adopted a limited-duration stockholder rights plan to protect the long-term value for all stockholders and ensure fair treatment in potential takeover situations [1][2][3] Summary by Sections Rights Plan Purpose - The Rights Plan aims to enable stockholders to realize long-term investment value and ensure fair treatment during any proposed takeover [2] - It is designed to prevent tactics that could allow control of the Company without appropriate compensation to all stockholders [2] - The plan was initiated in response to significant dislocation in the trading price of the Company's stock and interest from third parties to capitalize on this dislocation [2] Rights Plan Details - The Rights Plan applies equally to all current and future stockholders and does not deter offers or preclude the Board from considering beneficial transactions [3] - Fortrea will issue one right for each share of common stock as of June 23, 2025, with rights becoming exercisable if any person acquires 10% or more of the outstanding common stock [4] - If exercisable, rights holders (excluding the triggering person) can acquire shares at a 50% discount or exchange rights for one share of common stock [4] - The Board can redeem the rights at $0.001 per right, and the plan does not limit future Boards' ability to redeem the rights [4] Company Overview - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [6] - The Company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [6]

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE).Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=152581&from=4CLASS PERIOD: July 3, 20 ...

SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Fortrea Holdings Inc. (NASDAQ: FTRE). The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Fo ...

Core Viewpoint - Fortrea has appointed Anshul Thakral as CEO, effective August 4, 2025, succeeding Interim CEO Peter M. Neupert, who will remain as chairman of the board [3][4]. Company Leadership - Anshul Thakral brings over 20 years of experience in life sciences, focusing on executing Fortrea's transformation plan and enhancing profitable growth [4][6]. - Neupert praised Thakral's leadership capabilities, industry knowledge, and commitment to innovation, indicating he is well-suited to lead Fortrea [5]. Strategic Focus - Thakral aims to modernize the clinical trials process and enhance customer engagement while delivering profitable growth and value for shareholders [5][6]. - Fortrea is recognized for its strong reputation in scientific rigor and customer experience, which Thakral intends to build upon [5][6]. Company Background - Fortrea is a leading global contract research organization (CRO) that partners with biopharmaceutical, biotechnology, and medical device companies to accelerate healthcare innovation [7]. - The company offers comprehensive clinical trial management and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [7].

BENSALEM, Pa., June 11, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FORTREA HOLDINGS INC. (FTRE), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 1, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offi ...

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings, Inc. for allegedly making false and misleading statements regarding its financial performance and business prospects during the Class Period from July 3, 2023, to February 28, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition service agreements, leading to inflated EBITDA targets for 2025 [5]. - It is alleged that Fortrea's public statements were materially false and misleading, which resulted in investor damages when the true details became known [5]. Group 2: Participation Information - Investors who purchased Fortrea securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the Rosen Law Firm for more information [3][6].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [2]. - The company was spun off from Labcorp in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from pre-spin projects and overstated cost savings from exiting transition services agreements (TSAs) [3]. - It is alleged that Fortrea's EBITDA targets for 2025 were inflated, leading to an overstatement of the company's business viability and financial prospects [3]. Impact of Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a lack of material cost savings from exiting TSAs, resulting in a stock price drop of over 12% [4]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an 8% decline in stock price [5]. Financial Performance Disclosure - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming [6]. - The announcement led to a significant stock price drop of over 25% [6].

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...